O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	20	25	study
O	26	28	of
O	29	32	two
B-intervention	33	43	irinotecan
I-intervention	44	53	schedules
O	54	57	for
O	58	66	patients
O	67	71	with
O	72	82	metastatic
O	83	89	breast
O	90	96	cancer
O	97	107	refractory
O	108	110	to
O	111	113	an
O	114	127	anthracycline
O	127	128	,
O	129	130	a
O	131	137	taxane
O	137	138	,
O	139	141	or
O	142	146	both
O	146	147	.

O	148	149	A
O	150	158	pressing
O	159	163	need
O	164	170	exists
O	171	174	for
O	175	181	agents
O	182	188	active
O	189	196	against
O	197	210	anthracycline
O	210	211	-
O	212	214	or
O	215	221	taxane
O	221	222	-
O	222	232	refractory
O	233	243	metastatic
O	244	250	breast
O	251	257	cancer
O	258	259	(
O	259	262	MBC
O	262	263	)
O	263	264	,
O	265	267	or
O	268	272	both
O	272	273	.

O	274	282	Previous
O	283	291	clinical
O	292	298	trials
O	299	308	suggested
O	309	313	that
O	314	324	irinotecan
O	325	330	might
O	331	335	have
O	336	340	such
O	341	349	activity
O	349	350	.

O	351	353	We
O	354	363	conducted
O	364	368	this
O	369	380	multicenter
O	381	386	phase
O	387	389	II
O	390	395	study
O	396	398	to
O	399	405	assess
O	406	414	efficacy
O	415	418	and
O	419	431	tolerability
O	432	434	of
O	435	438	two
O	439	449	irinotecan
O	450	459	schedules
O	459	460	.

B-eligibility	461	464	MBC
I-eligibility	465	473	patients
I-eligibility	474	477	who
I-eligibility	478	489	experienced
I-eligibility	490	497	disease
I-eligibility	498	509	progression
I-eligibility	510	515	after
I-eligibility	516	519	one
I-eligibility	520	522	to
I-eligibility	523	528	three
I-eligibility	529	541	chemotherapy
I-eligibility	542	550	regimens
I-eligibility	550	551	,
I-eligibility	552	561	including
I-eligibility	562	564	at
I-eligibility	565	570	least
I-eligibility	571	574	one
I-eligibility	575	588	anthracycline
I-eligibility	588	589	-
I-eligibility	590	592	or
I-eligibility	593	599	taxane
I-eligibility	599	600	-
I-eligibility	600	605	based
I-eligibility	606	613	regimen
O	613	614	,
O	615	619	were
O	620	628	randomly
O	629	637	assigned
O	638	640	to
O	641	651	irinotecan
O	652	654	in
O	655	656	6
O	656	657	-
O	657	661	week
O	662	668	cycles
O	669	679	comprising
O	680	683	100
O	684	686	mg
O	686	687	/
O	687	688	m
O	688	689	(
O	689	690	2
O	690	691	)
O	692	698	weekly
O	699	702	for
O	703	704	4
O	705	710	weeks
O	710	711	,
O	712	716	then
O	717	718	a
O	719	720	2
O	720	721	-
O	721	725	week
O	726	730	rest
O	731	732	(
O	732	738	weekly
O	738	739	)
O	740	742	or
O	743	746	240
O	747	749	mg
O	749	750	/
O	750	751	m
O	751	752	(
O	752	753	2
O	753	754	)
O	755	760	every
O	761	762	3
O	763	768	weeks
O	768	769	.

O	770	773	The
B-intervention	774	780	weekly
I-intervention	781	784	arm
O	785	788	had
B-intervention-participants	789	791	52
O	792	802	assessable
O	803	811	patients
O	811	812	;
O	813	816	the
B-control	817	822	every
I-control	822	823	-
I-control	823	824	3
I-control	824	825	-
I-control	825	830	weeks
I-control	831	834	arm
O	835	838	had
B-control-participants	839	841	51
O	842	852	assessable
O	853	861	patients
O	861	862	.

O	863	865	In
O	866	869	the
O	870	876	weekly
O	877	880	arm
O	880	881	,
O	882	885	the
B-outcome	886	895	objective
I-outcome	896	904	response
O	905	906	(
O	906	914	complete
O	915	925	regression
O	926	927	[
O	927	929	CR
O	929	930	]
O	931	932	+
O	933	940	partial
O	941	951	regression
O	952	953	[
O	953	955	PR
O	955	956	]
O	956	957	)
O	958	962	rate
O	963	966	was
B-iv-bin-percent	967	969	23
I-iv-bin-percent	969	970	%
O	971	972	(
B-iv-bin-abs	972	975	one
B-outcome	976	978	CR
O	978	979	,
B-iv-bin-abs	980	982	11
B-outcome	983	985	PR
O	985	986	;
O	987	989	95
O	989	990	%
O	991	993	CI
O	993	994	,
O	995	997	13
O	997	998	%
O	999	1001	to
O	1002	1004	37
O	1004	1005	%
O	1005	1006	)
O	1006	1007	.

B-outcome	1008	1014	Median
I-outcome	1015	1023	response
I-outcome	1024	1032	duration
O	1033	1036	was
B-iv-cont-median	1037	1038	4
I-iv-cont-median	1038	1039	.
I-iv-cont-median	1039	1040	9
I-iv-cont-median	1041	1047	months
O	1048	1049	(
O	1049	1054	range
O	1054	1055	,
O	1056	1057	1
O	1057	1058	.
O	1058	1059	9
O	1060	1062	to
O	1063	1065	15
O	1065	1066	.
O	1066	1067	9
O	1068	1074	months
O	1074	1075	)
O	1075	1076	,
O	1077	1080	and
B-outcome	1081	1087	median
I-outcome	1088	1095	overall
I-outcome	1096	1104	survival
O	1105	1108	was
B-iv-cont-median	1109	1110	9
I-iv-cont-median	1110	1111	.
I-iv-cont-median	1111	1112	7
I-iv-cont-median	1113	1119	months
O	1120	1121	(
O	1121	1123	95
O	1123	1124	%
O	1125	1127	CI
O	1127	1128	,
O	1129	1130	8
O	1130	1131	.
O	1131	1132	0
O	1133	1135	to
O	1136	1138	14
O	1138	1139	.
O	1139	1140	2
O	1141	1147	months
O	1147	1148	)
O	1148	1149	.

O	1150	1152	In
O	1153	1156	the
O	1157	1162	every
O	1162	1163	-
O	1163	1164	3
O	1164	1165	-
O	1165	1170	weeks
O	1171	1174	arm
O	1174	1175	,
O	1176	1179	the
B-outcome	1180	1189	objective
I-outcome	1190	1198	response
I-outcome	1199	1203	rate
O	1204	1207	was
B-cv-bin-percent	1208	1210	14
I-cv-bin-percent	1210	1211	%
O	1212	1213	(
B-cv-bin-abs	1213	1217	nine
B-outcome	1218	1220	PR
O	1220	1221	;
O	1222	1224	95
O	1224	1225	%
O	1226	1228	CI
O	1228	1229	,
O	1230	1231	6
O	1231	1232	%
O	1233	1235	to
O	1236	1238	26
O	1238	1239	%
O	1239	1240	)
O	1240	1241	,
B-outcome	1242	1248	median
I-outcome	1249	1257	response
I-outcome	1258	1266	duration
O	1267	1270	was
B-cv-cont-median	1271	1272	4
I-cv-cont-median	1272	1273	.
I-cv-cont-median	1273	1274	2
I-cv-cont-median	1275	1281	months
O	1282	1283	(
O	1283	1288	range
O	1288	1289	,
O	1290	1291	3
O	1291	1292	.
O	1292	1293	1
O	1294	1296	to
O	1297	1299	13
O	1299	1300	.
O	1300	1301	9
O	1302	1308	months
O	1308	1309	)
O	1309	1310	,
O	1311	1314	and
B-outcome	1315	1321	median
I-outcome	1322	1329	overall
I-outcome	1330	1338	survival
O	1339	1342	was
B-cv-cont-median	1343	1344	8
I-cv-cont-median	1344	1345	.
I-cv-cont-median	1345	1346	6
I-cv-cont-median	1347	1353	months
O	1354	1355	(
O	1355	1357	95
O	1357	1358	%
O	1359	1361	CI
O	1361	1362	,
O	1363	1364	7
O	1364	1365	.
O	1365	1366	0
O	1367	1369	to
O	1370	1372	12
O	1372	1373	.
O	1373	1374	3
O	1375	1381	months
O	1381	1382	)
O	1382	1383	.

O	1384	1393	Treatment
O	1394	1403	generally
O	1404	1407	was
B-outcome	1408	1412	well
I-outcome	1413	1422	tolerated
O	1422	1423	,
O	1424	1434	especially
O	1435	1437	in
O	1438	1441	the
O	1442	1448	weekly
O	1449	1452	arm
O	1452	1453	.

B-outcome	1454	1459	Grade
I-outcome	1460	1461	3
I-outcome	1462	1464	to
I-outcome	1465	1466	4
I-outcome	1467	1474	adverse
I-outcome	1475	1481	events
O	1482	1486	with
O	1487	1488	>
O	1489	1491	or
O	1492	1493	=
O	1494	1496	10
O	1496	1497	%
O	1498	1507	incidence
O	1508	1516	included
B-outcome	1517	1528	neutropenia
O	1529	1530	(
B-iv-bin-percent	1530	1532	29
I-iv-bin-percent	1532	1533	%
O	1533	1534	)
O	1535	1538	and
B-outcome	1539	1547	diarrhea
O	1548	1549	(
B-iv-bin-percent	1549	1551	17
I-iv-bin-percent	1551	1552	%
O	1552	1553	)
O	1554	1556	in
O	1557	1560	the
O	1561	1567	weekly
O	1568	1571	arm
O	1572	1575	and
B-outcome	1576	1587	neutropenia
O	1588	1589	(
B-cv-bin-percent	1589	1591	36
I-cv-bin-percent	1591	1592	%
O	1592	1593	)
O	1593	1594	,
B-outcome	1595	1603	vomiting
O	1604	1605	(
B-cv-bin-percent	1605	1607	20
I-cv-bin-percent	1607	1608	%
O	1608	1609	)
O	1609	1610	,
B-outcome	1611	1618	dyspnea
O	1619	1620	(
B-cv-bin-percent	1620	1622	18
I-cv-bin-percent	1622	1623	%
O	1623	1624	)
O	1624	1625	,
B-outcome	1626	1632	nausea
O	1633	1634	(
B-cv-bin-percent	1634	1636	16
I-cv-bin-percent	1636	1637	%
O	1637	1638	)
O	1638	1639	,
O	1640	1643	and
B-outcome	1644	1652	diarrhea
O	1653	1654	(
B-cv-bin-percent	1654	1656	12
I-cv-bin-percent	1656	1657	%
O	1657	1658	)
O	1659	1661	in
O	1662	1665	the
O	1666	1671	every
O	1671	1672	-
O	1672	1673	3
O	1673	1674	-
O	1674	1679	weeks
O	1680	1683	arm
O	1683	1684	.

O	1685	1695	Irinotecan
O	1696	1698	is
O	1699	1705	active
O	1706	1710	with
B-outcome	1711	1715	good
I-outcome	1716	1728	tolerability
O	1729	1731	in
O	1732	1742	refractory
O	1743	1746	MBC
O	1746	1747	.

O	1748	1758	Irinotecan
O	1759	1760	(
O	1760	1770	especially
O	1771	1777	weekly
O	1777	1778	)
O	1779	1787	warrants
O	1788	1798	additional
O	1799	1804	study
O	1805	1807	as
O	1808	1819	monotherapy
O	1820	1823	and
O	1824	1826	in
O	1827	1838	combination
O	1839	1847	regimens
O	1848	1850	in
O	1851	1855	this
O	1856	1863	setting
O	1863	1864	.
